(Q37115715)

18 August 2017

1 reference

title

Identification and treatment of prediabetes to prevent progression to type 2 diabetes (English)

1 reference

18 August 2017

0 references

Vivian A Fonseca

1

1 reference

18 August 2017

publication date

1 January 2007

1 reference

18 August 2017

1 reference

18 August 2017

volume

8

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

10-8; discussion 19-20

1 reference

Economic costs of diabetes in the US in 2002.

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

Clinical and cost-effectiveness of primary prevention of Type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

Lifestyle interventions are cost-effective in people with different levels of diabetes risk: results from a modeling study.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

Standards of medical care in diabetes--2007.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

A conceptual framework for targeting prediabetes with lifestyle, clinical, and behavioral management interventions

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

Effect of ramipril on the incidence of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

Efficacy of acarbose in Chinese subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

An update on the Diabetes Prevention Program

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

Nonhypoglycemic effects of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

Effect of torcetrapib on the progression of coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

Effect of weight loss with lifestyle intervention on risk of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

Hypertension treatment and implications of recent cardiovascular outcome trials

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2960004-1

7 January 2021

10.1016/S1098-3597(09)60004-1

Identifiers

DOI

1 reference

18 August 2017

1 reference